<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="b83e23d2-7598-4a24-a2ff-dd522905cc04"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use <content styleCode="bold">VASOPRESSIN IN SODIUM CHLORIDE INJECTION</content> safely and effectively.  See full prescribing information for <content styleCode="bold">VASOPRESSIN IN SODIUM CHLORIDE INJECTION</content>.<br/>
      <content styleCode="bold">VASOPRESSIN IN SODIUM CHLORIDE INJECTION, for intravenous use</content>
      <br/>Initial U.S. Approval: 2014</title>
   <effectiveTime value="20250221"/>
   <setId root="b5b2c367-6b7e-40be-a296-c4632f3e783f"/>
   <versionNumber value="4"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="005083209" root="1.3.6.1.4.1.519.1"/>
            <name>Baxter Healthcare Corporation</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="194684502" root="1.3.6.1.4.1.519.1"/>
                        <name>Baxter Healthcare Corporation</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-9640" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-9647" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-9640" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-9647" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-9640" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-9647" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84382" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="STERILIZE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-9640" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84382" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="STERILIZE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-9647" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-9640" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-9647" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="42861823-3ef8-4b22-97c0-07d8a649486e"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20230929"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0338-9640" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Vasopressin in 0.9% Sodium Chloride</name>
                        <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Vasopressin in 0.9% Sodium Chloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="[USP'U]" value="20"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="Y4907O6MFD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>VASOPRESSIN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Y4907O6MFD" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>VASOPRESSIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="900"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="33.6"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="TU7HW0W0QT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LACTATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="12"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0338-9640-12" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230929"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102842" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 9: Other Type of Part 3 Combination Product (e.g., Drug/Device/Biological Product)" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA217569" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230929"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0338-9647" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Vasopressin in 0.9% Sodium Chloride</name>
                        <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Vasopressin in 0.9% Sodium Chloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="[USP'U]" value="40"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="Y4907O6MFD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>VASOPRESSIN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Y4907O6MFD" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>VASOPRESSIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="900"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="33.6"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="TU7HW0W0QT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LACTATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="12"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0338-9647-12" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230929"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102842" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 9: Other Type of Part 3 Combination Product (e.g., Drug/Device/Biological Product)" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA217569" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230929"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_76bf1dd6-d085-4c7a-bcb4-a295448388b0">
               <id root="76bf1dd6-d085-4c7a-bcb4-a295448388b0"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE </title>
               <text>
                  <paragraph>Vasopressin in Sodium Chloride Injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.</paragraph>
               </text>
               <effectiveTime value="20230929"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Vasopressin in Sodium Chloride Injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. (<linkHtml href="#ID_76bf1dd6-d085-4c7a-bcb4-a295448388b0">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_e2997910-46c9-4982-8fa7-8fca1dfc5dd7">
               <id root="e2997910-46c9-4982-8fa7-8fca1dfc5dd7"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <effectiveTime value="20230929"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Post-cardiotomy shock: 0.03 units/minute to 0.1 units/minute by intravenous infusion. (<linkHtml href="#ID_1be5a26e-e397-4c57-952e-f27af47d5447">2.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Septic shock: 0.01 units/minute to 0.07 units/minute by intravenous infusion. (<linkHtml href="#ID_1be5a26e-e397-4c57-952e-f27af47d5447">2.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_1be5a26e-e397-4c57-952e-f27af47d5447">
                     <id root="1be5a26e-e397-4c57-952e-f27af47d5447"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Administration  </title>
                     <text>
                        <paragraph>This product does not require dilution prior to administration.</paragraph>
                        <paragraph>In general, titrate to the lowest dose compatible with a clinically acceptable response.</paragraph>
                        <paragraph>The recommended starting dose is:</paragraph>
                        <paragraph>
                           <content styleCode="italics">Post-cardiotomy shock:</content> 0.03 units/minute by intravenous infusion</paragraph>
                        <paragraph>
                           <content styleCode="italics">Septic Shock:</content> 0.01 units/minute by intravenous infusion</paragraph>
                        <paragraph>Titrate up by 0.005 units/minute at 10- to 15-minute intervals until the target blood pressure is reached. There are limited data for doses above 0.1 units/minute for post-cardiotomy shock and 0.07 units/minute for septic shock. Adverse reactions are expected to increase with higher doses.</paragraph>
                        <paragraph>After target blood pressure has been maintained for 8 hours without the use of catecholamines, taper vasopressin injection by 0.005 units/minute every hour as tolerated to maintain target blood pressure.</paragraph>
                        <paragraph>Inspect visually for any particulate matter and discoloration prior to administration. </paragraph>
                        <paragraph>Discard Unused Portion</paragraph>
                        <paragraph>Do not add supplemental medication or additive</paragraph>
                     </text>
                     <effectiveTime value="20230929"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_ff27980e-54da-49c0-b149-fb6a96dea507">
               <id root="ff27980e-54da-49c0-b149-fb6a96dea507"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>Injection:  a clear, practically colorless solution for intravenous infusion, supplied in 100-mL single dose ready-to-use containers as:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>20 units vasopressin (0.2 units/mL) in 0.9% sodium chloride </item>
                     <item>
                        <caption>•</caption>40 units vasopressin (0.4 units/mL) in 0.9% sodium chloride</item>
                  </list>
               </text>
               <effectiveTime value="20230929"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection:  100-mL single dose, ready-to-use containers with (<linkHtml href="#ID_ff27980e-54da-49c0-b149-fb6a96dea507">3</linkHtml>)</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>20 units vasopressin (0.2 units/mL) in 0.9% sodium chloride.</item>
                           <item>
                              <caption>•</caption>40 units vasopressin (0.4 units/mL) in 0.9% sodium chloride.</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_3a73aefc-3c46-484d-a6a2-20d1154308b2">
               <id root="3a73aefc-3c46-484d-a6a2-20d1154308b2"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS </title>
               <text>
                  <paragraph>Vasopressin in Sodium Chloride Injection is contraindicated in patients with a known allergy or hypersensitivity to 8-L-arginine vasopressin.</paragraph>
               </text>
               <effectiveTime value="20230929"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Vasopressin in Sodium Chloride Injection is contraindicated in patients with known allergy or hypersensitivity to 8-L-arginine vasopressin. (<linkHtml href="#ID_3a73aefc-3c46-484d-a6a2-20d1154308b2">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_6d02ccd6-2fa8-40e2-ae57-f08a1bb72eb9">
               <id root="6d02ccd6-2fa8-40e2-ae57-f08a1bb72eb9"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS </title>
               <effectiveTime value="20230929"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Can worsen cardiac function (<linkHtml href="#ID_390973bf-7756-4cab-87c8-7de140676ea7">5.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Reversible diabetes insipidus (<linkHtml href="#ID_faae4c08-52ff-4af8-80cb-7555b9fcc552">5.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_390973bf-7756-4cab-87c8-7de140676ea7">
                     <id root="390973bf-7756-4cab-87c8-7de140676ea7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Worsening Cardiac Function  </title>
                     <text>
                        <paragraph>A decrease in cardiac index may be observed with the use of vasopressin.</paragraph>
                     </text>
                     <effectiveTime value="20230929"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_faae4c08-52ff-4af8-80cb-7555b9fcc552">
                     <id root="faae4c08-52ff-4af8-80cb-7555b9fcc552"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Reversible Diabetes Insipidus  </title>
                     <text>
                        <paragraph>Patients may experience reversible diabetes insipidus, manifested by the development of polyuria, a dilute urine, and hypernatremia, after cessation of treatment with vasopressin. Monitor serum electrolytes, fluid status and urine output after vasopressin discontinuation. Some patients may require readministration of vasopressin or administration of desmopressin to correct fluid and electrolyte shifts.</paragraph>
                     </text>
                     <effectiveTime value="20230929"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_85c2f5ed-dee7-4bfa-8011-029aa1459032">
               <id root="85c2f5ed-dee7-4bfa-8011-029aa1459032"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS </title>
               <text>
                  <paragraph>The following adverse reactions associated with the use of vasopressin were identified in the literature.  Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to estimate reliably their frequency or establish a causal relationship to drug exposure.</paragraph>
                  <paragraph>Bleeding/lymphatic system disorders: Hemorrhagic shock, decreased platelets, intractable bleeding</paragraph>
                  <paragraph>Cardiac disorders: Right heart failure, atrial fibrillation, bradycardia, myocardial ischemia</paragraph>
                  <paragraph>Gastrointestinal disorders: Mesenteric ischemia </paragraph>
                  <paragraph>Hepatobiliary: Increased bilirubin levels</paragraph>
                  <paragraph>Renal/urinary disorders: Acute renal insufficiency</paragraph>
                  <paragraph>Vascular disorders: Distal limb ischemia</paragraph>
                  <paragraph>Metabolic: Hyponatremia</paragraph>
                  <paragraph>Skin: Ischemic lesions</paragraph>
                  <paragraph>
                     <content styleCode="bold">Postmarketing Experience</content>
                  </paragraph>
                  <paragraph>Reversible diabetes insipidus <content styleCode="italics">[<linkHtml href="#ID_faae4c08-52ff-4af8-80cb-7555b9fcc552">see Warnings and Precautions (5.2)</linkHtml>]</content>
                  </paragraph>
               </text>
               <effectiveTime value="20230929"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions include decreased cardiac output, bradycardia, tachyarrhythmias, hyponatremia and ischemia (coronary, mesenteric, skin, digital). (<linkHtml href="#ID_85c2f5ed-dee7-4bfa-8011-029aa1459032">6</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact </content>
                           <content styleCode="bold">Baxter Healthcare at 1-866-888-2472</content>
                           <content styleCode="bold"> or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch.">www.fda.gov/medwatch.</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_365a8b90-b404-4e92-8ab0-924a5daf19c9">
               <id root="365a8b90-b404-4e92-8ab0-924a5daf19c9"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS </title>
               <effectiveTime value="20230929"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (<linkHtml href="#ID_7bd7f1e7-d1cd-4590-ac75-3127bbc32c2a">7.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. (<linkHtml href="#ID_b998ea13-f97a-448a-b60b-9eb4a35ddb5a">7.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Co-administration of ganglionic blockers or drugs causing SIADH (syndrome of inappropriate antiduretic hormone secretion) may increase the pressor response. (<linkHtml href="#ID_6cf86c0b-5313-4b43-98f8-ec2110b3b98d">7.3</linkHtml>, <linkHtml href="#ID_f493a11c-5dab-4b24-91db-6d14d30a9a81">7.4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Co-administration of drugs causing diabetes insipidus may decrease the pressor response. (<linkHtml href="#ID_f53d79f0-b036-4c35-97f4-7e0e1a7d4676">7.5</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_7bd7f1e7-d1cd-4590-ac75-3127bbc32c2a">
                     <id root="7bd7f1e7-d1cd-4590-ac75-3127bbc32c2a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Catecholamines </title>
                     <text>
                        <paragraph>Use with <content styleCode="italics">catecholamines</content> is expected to result in an additive effect on mean arterial blood pressure and other hemodynamic parameters. Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed.</paragraph>
                     </text>
                     <effectiveTime value="20230929"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_b998ea13-f97a-448a-b60b-9eb4a35ddb5a">
                     <id root="b998ea13-f97a-448a-b60b-9eb4a35ddb5a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Indomethacin </title>
                     <text>
                        <paragraph>Use with <content styleCode="italics">indomethacin</content> may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance. Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed <content styleCode="italics">[<linkHtml href="#ID_a47b6c06-e916-44ad-9b93-5cbbe83dd683">see Clinical Pharmacology (12.3)</linkHtml>]</content>
                           <content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230929"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_6cf86c0b-5313-4b43-98f8-ec2110b3b98d">
                     <id root="6cf86c0b-5313-4b43-98f8-ec2110b3b98d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3  Ganglionic Blocking Agents </title>
                     <text>
                        <paragraph>Use with <content styleCode="italics">ganglionic blocking agents</content> may increase the effect of Vasopressin in Sodium Chloride Injection on mean arterial blood pressure. Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed <content styleCode="italics">[</content>
                           <content styleCode="italics">
                              <linkHtml href="#ID_a47b6c06-e916-44ad-9b93-5cbbe83dd683">see Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230929"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_f493a11c-5dab-4b24-91db-6d14d30a9a81">
                     <id root="f493a11c-5dab-4b24-91db-6d14d30a9a81"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.4 Drugs Suspected of Causing SIADH </title>
                     <text>
                        <paragraph>Use with <content styleCode="italics">drugs suspected of causing SIADH</content> (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasopressin in Sodium Chloride Injection. Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed.</paragraph>
                     </text>
                     <effectiveTime value="20230929"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_f53d79f0-b036-4c35-97f4-7e0e1a7d4676">
                     <id root="f53d79f0-b036-4c35-97f4-7e0e1a7d4676"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.5 Drugs Suspected of Causing Diabetes Insipidus </title>
                     <text>
                        <paragraph>Use with <content styleCode="italics">drugs suspected of causing diabetes insipidus</content> (e.g., demeclocycline, lithium, foscarnet, clozapine) may decrease the pressor effect in addition to the antidiuretic effect of Vasopressin in Sodium Chloride Injection. Hemodynamic monitoring is recommended; adjust the dose of  vasopressin as needed.</paragraph>
                     </text>
                     <effectiveTime value="20230929"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_cd3587e0-8482-4bbd-9f19-7a47db0b775e">
               <id root="cd3587e0-8482-4bbd-9f19-7a47db0b775e"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20230929"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="bold">Pregnancy: </content>May induce tonic uterine contractions. (<linkHtml href="#ID_08ee63a8-a538-44a8-ab3f-f12a1225218d">8.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="bold">Pediatric Use: </content> Safety and effectiveness have not been established. (<linkHtml href="#ID_009001a6-5c08-400a-9c2d-a00c7524669c">8.4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="bold">Geriatric Use: </content>No safety issues have not been identified in older patients. (<linkHtml href="#ID_1b20937b-d828-47d2-9d34-a811995179cd">8.5</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_08ee63a8-a538-44a8-ab3f-f12a1225218d">
                     <id root="08ee63a8-a538-44a8-ab3f-f12a1225218d"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no available data on Vasopressin in Sodium Chloride Injection use in pregnant women to inform a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted.</paragraph>
                        <paragraph>Clinical Considerations</paragraph>
                        <list listType="ordered">
                           <item>
                              <caption> </caption>
                              <content styleCode="italics">Dose Adjustments During Pregnancy and the Postpartum Period: </content>Because of increased clearance of vasopressin in the second and third trimester, the dose of Vasopressin in Sodium Chloride Injection may need to be increased <content styleCode="italics">[<linkHtml href="#ID_1be5a26e-e397-4c57-952e-f27af47d5447">see Dosage and Administration (2.1)</linkHtml> and <linkHtml href="#ID_a47b6c06-e916-44ad-9b93-5cbbe83dd683">Clinical Pharmacology (12.3)</linkHtml>].</content>
                           </item>
                           <item>
                              <caption> </caption>
                              <content styleCode="italics">Maternal Adverse Reactions: </content>Vasopressin in Sodium Chloride Injection may produce tonic uterine contractions that could threaten the continuation of pregnancy.</item>
                        </list>
                     </text>
                     <effectiveTime value="20230929"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_c5bb7da1-55d0-4a26-abb0-8a1dd15dc879">
                     <id root="c5bb7da1-55d0-4a26-abb0-8a1dd15dc879"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation </title>
                     <text>
                        <paragraph>There are no data on the presence of vasopressin injection in either human or animal milk, the effects on the breastfed infant, or the effects on milk production.</paragraph>
                     </text>
                     <effectiveTime value="20230929"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_009001a6-5c08-400a-9c2d-a00c7524669c">
                     <id root="009001a6-5c08-400a-9c2d-a00c7524669c"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use </title>
                     <text>
                        <paragraph>Safety and effectiveness of Vasopressin in Sodium Chloride Injection in pediatric patients with vasodilatory shock have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20230929"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_1b20937b-d828-47d2-9d34-a811995179cd">
                     <id root="1b20937b-d828-47d2-9d34-a811995179cd"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use </title>
                     <text>
                        <paragraph>Clinical studies of vasopressin did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy <content styleCode="italics">[<linkHtml href="#ID_6d02ccd6-2fa8-40e2-ae57-f08a1bb72eb9">see Warnings and Precautions (5)</linkHtml>, <linkHtml href="#ID_85c2f5ed-dee7-4bfa-8011-029aa1459032">Adverse Reactions (6)</linkHtml>, and <linkHtml href="#ID_a47b6c06-e916-44ad-9b93-5cbbe83dd683">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230929"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_9f740fb0-f723-4fb3-8322-57184bc7c498">
               <id root="9f740fb0-f723-4fb3-8322-57184bc7c498"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE </title>
               <text>
                  <paragraph>Overdosage with Vasopressin in Sodium Chloride Injection can be expected to manifest as consequences of vasoconstriction of various vascular beds (peripheral, mesenteric, and coronary) and as hyponatremia. In addition, overdosage may lead less commonly to ventricular tachyarrhythmias (including Torsade de Pointes), rhabdomyolysis, and non-specific gastrointestinal symptoms.</paragraph>
                  <paragraph>Direct effects will resolve within minutes of withdrawal of treatment.</paragraph>
               </text>
               <effectiveTime value="20230929"/>
            </section>
         </component>
         <component>
            <section ID="ID_38cc66f8-84ed-47d9-9ada-82afb6403ebd">
               <id root="38cc66f8-84ed-47d9-9ada-82afb6403ebd"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>Vasopressin in Sodium Chloride Injection contains vasopressin, a polypeptide hormone. The chemical name of vasopressin is Cyclo (1-6) L-Cysteinyl-L-Tyrosyl-L-Phenylalanyl-L-Glutaminyl-L-Asparaginyl-L-Cysteinyl-L-Prolyl-L-Arginyl-L-Glycinamide. It is a white to off-white amorphous powder, freely soluble in water. The structural formula is:</paragraph>
                  <renderMultiMedia ID="id-544828194" referencedObject="ID_1f079789-7f2a-42bc-a68e-de669b5ed465"/>
                  <paragraph>Molecular Formula: C<sub>46</sub>H<sub>65</sub>N<sub>15</sub>O<sub>12</sub>S<sub>2</sub>  Molecular Weight: 1084.23</paragraph>
                  <paragraph>Vasopressin in Sodium Chloride Injection is a sterile, aqueous solution of synthetic arginine vasopressin for intravenous administration. Each 100 mL contains 20 units (0.2 units/mL) or 40 units (0.4 units/mL) of vasopressin.  Each 100mL also contains 900 mg Sodium Chloride, 33.6 mg Sodium DL-Lactate, and Water for Injection.  pH may have been adjusted with sodium hydroxide and/or hydrochloric acid. It has a pH of 3.6 – 4.0.</paragraph>
               </text>
               <effectiveTime value="20230929"/>
               <component>
                  <observationMedia ID="ID_1f079789-7f2a-42bc-a68e-de669b5ed465">
                     <text>Vasopressin Structural Formula</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_bffedcb2-48be-4fd9-b599-199b2d347090">
               <id root="bffedcb2-48be-4fd9-b599-199b2d347090"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20230929"/>
               <component>
                  <section ID="ID_08bd7127-e552-44dc-a2a8-b02fd82f5d9d">
                     <id root="08bd7127-e552-44dc-a2a8-b02fd82f5d9d"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action </title>
                     <text>
                        <paragraph>Vasopressin causes vasoconstriction by binding to V<sub>1</sub> receptors on vascular smooth muscle coupled to the Gq/11-phospholipase C-phosphatidyl-inositol-triphosphate pathway, resulting in the release of intracellular calcium. In addition, vasopressin stimulates antidiuresis via stimulation of V<sub>2</sub> receptors which are coupled to adenyl cyclase.</paragraph>
                     </text>
                     <effectiveTime value="20230929"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_4d73f85d-4396-44d7-8b6a-d135d8ec9db8">
                     <id root="4d73f85d-4396-44d7-8b6a-d135d8ec9db8"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics </title>
                     <text>
                        <paragraph>At therapeutic doses exogenous vasopressin elicits a vasoconstrictive effect in most vascular beds including the splanchnic, renal and cutaneous circulation. In addition, vasopressin at pressor doses triggers contractions of smooth muscles in the gastrointestinal tract mediated by muscular V<sub>1</sub>-receptors and release of prolactin and ACTH via V<sub>3</sub> receptors. At lower concentrations typical for the antidiuretic hormone vasopressin inhibits water diuresis via renal V<sub>2</sub> receptors. In addition, vasopressin has been demonstrated to cause vasodilation in numerous vascular beds that are mediated by V<sub>2</sub>, V<sub>3</sub>, oxytocin and purinergic P2 receptors.</paragraph>
                        <paragraph>In patients with vasodilatory shock vasopressin in therapeutic doses increases systemic vascular resistance and mean arterial blood pressure and reduces the dose requirements for norepinephrine. Vasopressin tends to decrease heart rate and cardiac output. The pressor effect is proportional to the infusion rate of exogenous vasopressin. The pressor effect reaches its peak within 15 minutes. After stopping the infusion the pressor effect fades within 20 minutes. There is no evidence for tachyphylaxis or tolerance to the pressor effect of vasopressin in patients.</paragraph>
                     </text>
                     <effectiveTime value="20230929"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a47b6c06-e916-44ad-9b93-5cbbe83dd683">
                     <id root="a47b6c06-e916-44ad-9b93-5cbbe83dd683"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics </title>
                     <text>
                        <paragraph>Vasopressin plasma concentrations increase linearly with increasing infusion rates from 10 to 200 μU/kg/min. Steady state plasma concentrations are achieved after 30 minutes of continuous intravenous infusion.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Vasopressin does not appear to bind plasma protein. The volume of distribution is 140 mL/kg.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>At infusion rates used in vasodilatory shock (0.01 to 0.1 units/minute), the clearance of vasopressin is 9 to 25 mL/min/kg in patients with vasodilatory shock. The apparent t<sub>1/2</sub> of vasopressin at these levels is ≤10 minutes.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Metabolism</content>
                        </paragraph>
                        <paragraph>Serine protease, carboxipeptidase and disulfide oxido-reductase cleave vasopressin at sites relevant for the pharmacological activity of the hormone. Thus, the generated metabolites are not expected to retain important pharmacological activity.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Excretion</content>
                        </paragraph>
                        <paragraph>Vasopressin is predominantly metabolized and only about 6% of the dose is excreted unchanged into urine.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <list listType="ordered">
                           <item>
                              <caption> </caption>
                              <content styleCode="italics">Pregnancy: </content>Because of a spillover into blood of placental vasopressinase, the clearance of exogenous and endogenous vasopressin increases gradually over the course of a pregnancy. During the first trimester of pregnancy, the clearance is only slightly increased. However, by the third trimester the clearance of vasopressin is increased about 4-fold and at term up to 5-fold. After delivery, the clearance of vasopressin returns to pre-conception baseline within two weeks<content styleCode="italics">.</content>
                           </item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <list listType="ordered">
                           <item>
                              <caption> </caption>Indomethacin more than doubles the time to offset for vasopressin’s effect on peripheral vascular resistance and cardiac output in healthy subjects<content styleCode="italics"> [<linkHtml href="#ID_b998ea13-f97a-448a-b60b-9eb4a35ddb5a">see Drug Interactions (7.2)</linkHtml>].</content>
                           </item>
                           <item>
                              <caption> </caption>The ganglionic blocking agent tetra-ethylammonium increases the pressor effect of vasopressin by 20% in healthy subjects <content styleCode="italics">[<linkHtml href="#ID_6cf86c0b-5313-4b43-98f8-ec2110b3b98d">see Drug Interactions (7.3)</linkHtml>].</content>
                           </item>
                           <item>
                              <caption> </caption>Halothane, morphine, fentanyl, alfentanyl and sufentanyl do not impact exposure to endogenous vasopressin.</item>
                        </list>
                     </text>
                     <effectiveTime value="20230929"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_8a381adb-c647-456c-bbfd-2b5217177211">
               <id root="8a381adb-c647-456c-bbfd-2b5217177211"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY </title>
               <effectiveTime value="20230929"/>
               <component>
                  <section ID="ID_e795eb79-39a4-4bd3-9583-95e5e67d8dfe">
                     <id root="e795eb79-39a4-4bd3-9583-95e5e67d8dfe"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </title>
                     <text>
                        <paragraph>No formal carcinogenicity or fertility studies with vasopressin have been conducted in animals. Vasopressin was found to be negative in the <content styleCode="italics">in vitro</content> bacterial mutagenicity (Ames) test and the in vitro Chinese hamster ovary (CHO) cell chromosome aberration test. In mice, vasopressin has been reported to have an effect on function and fertilizing ability of spermatozoa.</paragraph>
                     </text>
                     <effectiveTime value="20230929"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_2c6f31e8-356d-4694-a7ec-d446b5ae58db">
                     <id root="2c6f31e8-356d-4694-a7ec-d446b5ae58db"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2 Animal Toxicology and/or Pharmacology </title>
                     <text>
                        <paragraph>No toxicology studies were conducted with vasopressin.</paragraph>
                     </text>
                     <effectiveTime value="20230929"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_f546d50d-e625-4404-9b45-c9373f5909d3">
               <id root="f546d50d-e625-4404-9b45-c9373f5909d3"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES </title>
               <text>
                  <paragraph>Increases in systolic and mean blood pressure following administration of vasopressin were observed in 7 studies in septic shock and 8 in post-cardiotomy vasodilatory shock.</paragraph>
               </text>
               <effectiveTime value="20230929"/>
            </section>
         </component>
         <component>
            <section ID="ID_0893a0c9-d31d-466e-850b-8190b121ed9b">
               <id root="ac68740f-272e-4fa0-95ce-d92d07365a62"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <text>
                  <paragraph>Vasopressin in Sodium Chloride Injection is supplied as a clear, practically colorless solution for intravenous administration in single-dose 100 mL ready-to-use containers available as:</paragraph>
                  <table styleCode="Noautorules" width="100%">
                     <col width="19%"/>
                     <col width="41%"/>
                     <col width="18%"/>
                     <tbody>
                        <tr>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Product Code</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Product Description</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">NDC Number</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>2G3498</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>20 units vasopressin (0.2 units/mL)</paragraph>
                              <paragraph>Supplied as 12 bags per carton</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>0338-9640-12</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>2G3499</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>40 units vasopressin (0.4 units/mL)</paragraph>
                              <paragraph>Supplied as 12 bags per carton</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>0338-9647-12</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Store in the refrigerator (2°C to 8°C [36°F to 46°F]). Protect from freezing.</paragraph>
                  <paragraph>If needed, Vasopressin in Sodium Chloride Injection may be stored at room temperature up to 25°C (77°F) for up to 6 months. Discard after 6 months if stored at room temperature or until the expiration date printed on the carton and container label, whichever is earlier. Once stored at room temperature, do not place back in the refrigerator.</paragraph>
                  <paragraph>The drug product must be stored in its light protective carton during storage.</paragraph>
                  <paragraph>Manufactured by, Packed by, Distributed by:</paragraph>
                  <paragraph>Baxter Healthcare Corporation</paragraph>
                  <paragraph>Deerfield, IL 60015 USA</paragraph>
                  <paragraph>Printed in USA</paragraph>
                  <paragraph>07-19-06-884</paragraph>
                  <paragraph>Baxter and Galaxy are trademarks of Baxter International Inc.</paragraph>
               </text>
               <effectiveTime value="20240205"/>
            </section>
         </component>
         <component>
            <section ID="ID_552528b6-67d4-4011-8bc2-58d919b14e8a">
               <id root="a88b5f42-2c77-49d9-b68f-8ec84bf8d8ec"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL </title>
               <text>
                  <renderMultiMedia ID="id-950240552" referencedObject="ID_2c59f0d3-d1f0-4ef4-afed-183fa430de89"/>
                  <renderMultiMedia ID="id-79524980" referencedObject="ID_42857de3-8024-4bbf-9314-481b396e4b52">
                     <caption>Container Label</caption>
                  </renderMultiMedia>
                  <paragraph>
                     <content styleCode="bold">NDC 0338-9640-12</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Vasopressin</content>
                     <br/>
                     <content styleCode="bold">in 0.9% Sodium Chloride Injection</content>
                     <br/>
                     <content styleCode="bold">20 units per 100 mL</content>
                     <br/>(<content styleCode="bold">0.2 units/mL)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Intravenous Infusion Only</content>
                     <br/>100 mL Single-Dose Container<br/>Discard Unused Portion</paragraph>
                  <paragraph>Rx only<br/>Sterile</paragraph>
                  <paragraph>Each mL of the 0.2 units/mL strength also contains<br/>9 mg sodium chloride, 0.336 mg sodium DL-lactate,<br/>and water for injection. pH may have been adjusted<br/>with sodium hydroxide or hydrochloric acid.</paragraph>
                  <paragraph>Dosage: See prescribing information.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Store refrigerated (2°C to 8°C [36°F to 46°F]).</content>
                  </paragraph>
                  <paragraph>If needed, product may be stored at room<br/>temperature up to 25°C (77°F) for up to 6 months.<br/>Discard after 6 months if stored at room<br/>temperature.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Protect from light. Protect from freezing.</content>
                  </paragraph>
                  <paragraph>Do not add supplemental medication or additives.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Code 2G3498</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Baxter</content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics">Logo</content>
                     </content>
                     <br/>
                     <content styleCode="bold">Baxter Healthcare Corporation,</content> Deerfield, IL 60015 USA</paragraph>
                  <paragraph>Product of USA<br/>07-34-00-2342</paragraph>
                  <paragraph>BAR CODE<br/>POSITION ONLY UPCA-A</paragraph>
                  <paragraph>303389640127</paragraph>
                  <renderMultiMedia ID="id-557702678" referencedObject="ID_69add9d8-b7b9-4588-827a-fd4e0075be0c"/>
                  <renderMultiMedia ID="id1354757104" referencedObject="c9f420fb-b095-4e4e-b2ed-93bc296c3a3b">
                     <caption>Container Label</caption>
                  </renderMultiMedia>
                  <paragraph>
                     <content styleCode="bold">NDC 0338-9647-12</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Vasopressin</content>
                     <br/>
                     <content styleCode="bold">in 0.9% Sodium Chloride Injection<br/>40 units per 100 mL</content>
                     <br/>(<content styleCode="bold">0.4 units/mL)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Intravenous Infusion Only</content>
                     <br/>100 mL Single-Dose Container<br/>Discard Unused Portion</paragraph>
                  <paragraph>Rx only<br/>Sterile</paragraph>
                  <paragraph>Each mL of the 0.4 units/mL strength also contains<br/>9 mg sodium chloride, 0.336 mg sodium DL-lactate,<br/>and water for injection. pH may have been adjusted<br/>with sodium hydroxide or hydrochloric acid.</paragraph>
                  <paragraph>Dosage: See prescribing information.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Store refrigerated (2°C to 8°C [36°F to 46°F]).</content>
                  </paragraph>
                  <paragraph>If needed, product may be stored at room<br/>temperature up to 25°C (77°F) for up to 6 months.<br/>Discard after 6 months if stored at room<br/>temperature.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Protect from light. Protect from freezing.</content>
                  </paragraph>
                  <paragraph>Do not add supplemental medication or additives.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Code 2G3499</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Baxter Logo</content>
                     </content>
                     <br/>
                     <content styleCode="bold">Baxter Healthcare Corporation,</content> Deerfield, IL 60015 USA</paragraph>
                  <paragraph>Product of USA<br/>07-34-00-2343</paragraph>
                  <paragraph>BAR CODE<br/>POSITION ONLY UPCA-A</paragraph>
                  <paragraph>303389647126</paragraph>
                  <renderMultiMedia ID="id2123871647" referencedObject="ID_83c6fd5e-c353-47db-8dbd-c0106c6bbc82"/>
                  <renderMultiMedia ID="id-411395707" referencedObject="ID_798485f3-c898-4b61-a0ee-649eeadd9ab4">
                     <caption>Carton Label</caption>
                  </renderMultiMedia>
                  <paragraph>
                     <content styleCode="bold">Store refrigerated (2°C to 8°C [36°F to 46°F]).</content>
                  </paragraph>
                  <paragraph>If needed, product may be stored at room temperature up to 25°C (77°F) for up to 6 months.<br/>Discard after 6 months if stored at room temperature.</paragraph>
                  <paragraph>
                     <content styleCode="bold">The drug product must be stored in its light protective carton during storage.<br/>Protect from freezing.</content>
                  </paragraph>
                  <paragraph>Do not add supplemental medication or additives.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Vasopressin</content>
                     <br/>
                     <content styleCode="bold">in 0.9% Sodium Chloride Injection<br/>20 units per 100 mL</content>
                     <content styleCode="bold">(0.2 units/mL)</content>
                  </paragraph>
                  <paragraph>Contains: 6 x 100 mL Single-Dose bags.<br/>Each bag contains 100 mL.</paragraph>
                  <paragraph>
                     <content styleCode="italics">
                        <content styleCode="bold">Baxter</content>
                        <content styleCode="bold">Logo</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 0338-9640-12<br/>Code 2G3498</content>
                  </paragraph>
                  <paragraph>*FOR BAR CODE POSITION ONLY</paragraph>
                  <paragraph>(01) 20303389640121</paragraph>
                  <paragraph>
                     <content styleCode="bold">For Intravenous Infusion only<br/>
                     </content>Each mL of the 0.2 units/mL strength also contains 9 mg sodium chloride, 0.336 mg sodium DL-lactate, and water<br/>for injection. pH may have been adjusted with sodium hydroxide and/or hydrochloric acid.<br/>Dosage: See prescribing information.</paragraph>
                  <paragraph>Baxter Healthcare Corporation,<content styleCode="bold"/>Deerfield, IL 60015 USA</paragraph>
                  <paragraph>07-04-00-1385</paragraph>
                  <renderMultiMedia ID="id-1467347784" referencedObject="ID_74c2450c-62d8-472a-ad46-edd2c2470137"/>
                  <renderMultiMedia ID="id960927219" referencedObject="ID_8a8b463c-19d3-4887-a3fc-438dc23d7514">
                     <caption>Carton Label</caption>
                  </renderMultiMedia>
                  <paragraph>
                     <content styleCode="bold">Store refrigerated (2°C to 8°C [36°F to 46°F]).</content>
                  </paragraph>
                  <paragraph>If needed, product may be stored at room temperature up to 25°C (77°F) for up to 6 months.<br/>Discard after 6 months if stored at room temperature.</paragraph>
                  <paragraph>
                     <content styleCode="bold">The drug product must be stored in its light protective carton during storage.<br/>Protect from freezing.</content>
                  </paragraph>
                  <paragraph>Do not add supplemental medication or additives.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Vasopressin</content>
                     <br/>
                     <content styleCode="bold">in 0.9% Sodium Chloride Injection<br/>40 units per 100 mL</content>
                     <br/>
                     <content styleCode="bold">(0.4 units/mL)</content>
                  </paragraph>
                  <paragraph>Contains: 6 x 100 mL Single-Dose bags.<br/>Each bag contains 100 mL.</paragraph>
                  <paragraph>
                     <content styleCode="italics">
                        <content styleCode="bold">Baxter</content>
                        <content styleCode="bold">Logo</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 0338-9647-12<br/>Code 2G3499</content>
                  </paragraph>
                  <paragraph>*FOR BAR CODE POSITION ONLY</paragraph>
                  <paragraph>(01) 20303389647120</paragraph>
                  <paragraph>
                     <content styleCode="bold">For Intravenous Infusion only<br/>
                     </content>Each mL of the 0.4 units/mL strength also contains 9 mg sodium chloride, 0.336 mg sodium DL-lactate, and water<br/>for injection. pH may have been adjusted with sodium hydroxide and/or hydrochloric acid.<br/>Dosage: See prescribing information.</paragraph>
                  <paragraph>Baxter Healthcare Corporation,<content styleCode="bold"/>Deerfield, IL 60015 USA</paragraph>
                  <paragraph>07-04-00-1401</paragraph>
               </text>
               <effectiveTime value="20250221"/>
               <component>
                  <observationMedia ID="ID_2c59f0d3-d1f0-4ef4-afed-183fa430de89">
                     <text>Vasopressin 20 9640-12 Representative Container Label (1 of 2)</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Image-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_42857de3-8024-4bbf-9314-481b396e4b52">
                     <text>Vasopressin 20 9640-12 Representative Container Label (2 of 2)</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Image-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_69add9d8-b7b9-4588-827a-fd4e0075be0c">
                     <text>Vasopressin 40 9647-12 Representative Container Label (1 of 2)</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Image-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="c9f420fb-b095-4e4e-b2ed-93bc296c3a3b">
                     <text>Vasopressin 40 9647-12 Representative Container Label (2 of 2)</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Image-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_83c6fd5e-c353-47db-8dbd-c0106c6bbc82">
                     <text>Vasopressin 20 9640-12 Representative Carton Label (1 of 2)</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Image-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_798485f3-c898-4b61-a0ee-649eeadd9ab4">
                     <text>Vasopressin 20 9640-12 Representative Carton Label (2 of 2)</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Image-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_74c2450c-62d8-472a-ad46-edd2c2470137">
                     <text>Vasopressin 40 9647-12 Representative Carton Label (1 of 2)</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Image-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_8a8b463c-19d3-4887-a3fc-438dc23d7514">
                     <text>Vasopressin 40 9647-12 Representative Carton Label (2 of 2)</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Image-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>